0001179110-16-030002.txt : 20160923
0001179110-16-030002.hdr.sgml : 20160923
20160923170903
ACCESSION NUMBER: 0001179110-16-030002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160921
FILED AS OF DATE: 20160923
DATE AS OF CHANGE: 20160923
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quisel John D
CENTRAL INDEX KEY: 0001586788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 161900474
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2016-09-21
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586788
Quisel John D
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP, Bus. Dev., GC & Secretary
Common Stock
2016-09-21
4
M
0
781
7.12
A
77004
D
Common Stock
2016-09-21
4
M
0
13671
24.11
A
90675
D
Common Stock
2016-09-21
4
M
0
11500
3.88
A
102175
D
Common Stock
2016-09-21
4
S
0
45952
38.05
D
56223
D
Option to Purchase Common Stock
7.12
2016-09-21
4
M
0
781
0
D
2022-12-12
Common Stock
781
1562
D
Option to Purchase Common Stock
24.11
2016-09-21
4
M
0
13671
0
D
2023-12-05
Common Stock
13671
15329
D
Option to Purchase Common Stock
3.88
2016-09-21
4
M
0
11500
0
D
2020-12-02
Common Stock
11500
5000
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.
/s/ John D. Quisel
2016-09-23